
## Petr Novak

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8364614/publications.pdf Version: 2024-02-01



DETD NOVAK

#	Article	IF	CITATIONS
1	ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease. Nature Aging, 2021, 1, 521-534.	11.6	64
2	Nanobiotechnology in Neurodegenerative Diseases. , 2019, , 65-138.		4
3	Ten Years of Tau-Targeted Immunotherapy: The Path Walked and the Roads Ahead. Frontiers in Neuroscience, 2018, 12, 798.	2.8	67
4	FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease. Alzheimer's Research and Therapy, 2018, 10, 108.	6.2	87
5	Tau Conformation as a Target for Disease-Modifying Therapy: The Role of Truncation. Journal of Alzheimer's Disease, 2018, 64, S535-S546.	2.6	29
6	Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurology, The, 2017, 16, 123-134.	10.2	233
7	O4-08-01: Characterisation of the Antibody Response to AADVAC1: The First-in-Kind Active Vaccine Against Neurofibrillary TAU Pathology. , 2016, 12, P351-P351.		0
8	First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model. Alzheimer's Research and Therapy, 2014, 6, 44.	6.2	193